| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 27-31 |
| Number of pages | 5 |
| Journal | Pharma Times |
| Volume | 45 |
| Issue number | 1 |
| Publication status | Published - 2013 |
Cite this
Moorkoth, S., Gujar, Y., & Bukka, D. (2013). Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars. Pharma Times, 45(1), 27-31.
@article{ce5fc66ff1d44b2dbbb237fdb16413bc,
title = "Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars",
author = "S. Moorkoth and Y. Gujar and D. Bukka",
note = "cited By 0",
year = "2013",
language = "Undefined/Unknown",
volume = "45",
pages = "27--31",
journal = "Pharma Times",
issn = "0031-6849",
publisher = "Indian Pharmaceutical Association",
number = "1",
}
Moorkoth, S, Gujar, Y & Bukka, D 2013, 'Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars', Pharma Times, vol. 45, no. 1, pp. 27-31.
Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars. / Moorkoth, S.; Gujar, Y.; Bukka, D.
In: Pharma Times, Vol. 45, No. 1, 2013, p. 27-31.Research output: Contribution to journal › Article
TY - JOUR
T1 - Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars
AU - Moorkoth, S.
AU - Gujar, Y.
AU - Bukka, D.
N1 - cited By 0
PY - 2013
Y1 - 2013
M3 - Article
VL - 45
SP - 27
EP - 31
JO - Pharma Times
JF - Pharma Times
SN - 0031-6849
IS - 1
ER -
Moorkoth S, Gujar Y, Bukka D. Can India repeat the success of generics in US (United States) biosimilar market? an analysis of current FDA's stand on biosimilars. Pharma Times. 2013;45(1):27-31.